Shots:

• PeptiDream to receive an upfront along with R&D funding and may eligible for ~$2.2B in development- regulatory- and commercial milestones upon specified achievement along with royalties on sales on any Alnylam products
• The agreement will utilize PeptiDream’s peptide discovery platform with Alnylam’s siRNA-conjugate-based delivery to identify peptide ligands
• The collaboration will helps to yield multiple treatment opportunities at targeting disease-causing mRNA transcripts in a broad variety of tissue types

  | Ref: Businesswire | Image: Alnylam